Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Véronique Leblond, Efstathios Kastritis, Ranjana Advani, Stephen M. Ansell, Christian Buske, Jorge J. Castillo, Ramón García-Sanz, Morie Gertz, Eva Kimby, Charalampia Kyriakou, Giampaolo Merlini, Monique C. Minnema, Pierre Morel, Enrica Morra, Mathias Rummel, Ashutosh Wechalekar, Christopher J. Patterson, Steven P. Treon, Meletios A. Dimopoulos

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.

Original languageEnglish
Pages (from-to)1321-1328
Number of pages8
JournalBlood
Volume128
Issue number10
DOIs
Publication statusPublished - Sep 8 2016

Fingerprint

Waldenstrom Macroglobulinemia
Proteasome Inhibitors
Cells
Education
Dexamethasone
Sirolimus
Cyclophosphamide
B-Lymphocytes
Clinical Trials
Therapeutics
Lymphoproliferative Disorders
Advisory Committees
Mutation

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., ... Dimopoulos, M. A. (2016). Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 128(10), 1321-1328. https://doi.org/10.1182/blood-2016-04-711234

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. / Leblond, Véronique; Kastritis, Efstathios; Advani, Ranjana; Ansell, Stephen M.; Buske, Christian; Castillo, Jorge J.; García-Sanz, Ramón; Gertz, Morie; Kimby, Eva; Kyriakou, Charalampia; Merlini, Giampaolo; Minnema, Monique C.; Morel, Pierre; Morra, Enrica; Rummel, Mathias; Wechalekar, Ashutosh; Patterson, Christopher J.; Treon, Steven P.; Dimopoulos, Meletios A.

In: Blood, Vol. 128, No. 10, 08.09.2016, p. 1321-1328.

Research output: Contribution to journalReview article

Leblond, V, Kastritis, E, Advani, R, Ansell, SM, Buske, C, Castillo, JJ, García-Sanz, R, Gertz, M, Kimby, E, Kyriakou, C, Merlini, G, Minnema, MC, Morel, P, Morra, E, Rummel, M, Wechalekar, A, Patterson, CJ, Treon, SP & Dimopoulos, MA 2016, 'Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia', Blood, vol. 128, no. 10, pp. 1321-1328. https://doi.org/10.1182/blood-2016-04-711234
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321-1328. https://doi.org/10.1182/blood-2016-04-711234
Leblond, Véronique ; Kastritis, Efstathios ; Advani, Ranjana ; Ansell, Stephen M. ; Buske, Christian ; Castillo, Jorge J. ; García-Sanz, Ramón ; Gertz, Morie ; Kimby, Eva ; Kyriakou, Charalampia ; Merlini, Giampaolo ; Minnema, Monique C. ; Morel, Pierre ; Morra, Enrica ; Rummel, Mathias ; Wechalekar, Ashutosh ; Patterson, Christopher J. ; Treon, Steven P. ; Dimopoulos, Meletios A. / Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. In: Blood. 2016 ; Vol. 128, No. 10. pp. 1321-1328.
@article{7a7bad8595a041c6b148d5b77a34d568,
title = "Treatment recommendations from the Eighth International Workshop on Waldenstr{\"o}m's Macroglobulinemia",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenstr{\"o}m's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.",
author = "V{\'e}ronique Leblond and Efstathios Kastritis and Ranjana Advani and Ansell, {Stephen M.} and Christian Buske and Castillo, {Jorge J.} and Ram{\'o}n Garc{\'i}a-Sanz and Morie Gertz and Eva Kimby and Charalampia Kyriakou and Giampaolo Merlini and Minnema, {Monique C.} and Pierre Morel and Enrica Morra and Mathias Rummel and Ashutosh Wechalekar and Patterson, {Christopher J.} and Treon, {Steven P.} and Dimopoulos, {Meletios A.}",
year = "2016",
month = "9",
day = "8",
doi = "10.1182/blood-2016-04-711234",
language = "English",
volume = "128",
pages = "1321--1328",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

AU - Leblond, Véronique

AU - Kastritis, Efstathios

AU - Advani, Ranjana

AU - Ansell, Stephen M.

AU - Buske, Christian

AU - Castillo, Jorge J.

AU - García-Sanz, Ramón

AU - Gertz, Morie

AU - Kimby, Eva

AU - Kyriakou, Charalampia

AU - Merlini, Giampaolo

AU - Minnema, Monique C.

AU - Morel, Pierre

AU - Morra, Enrica

AU - Rummel, Mathias

AU - Wechalekar, Ashutosh

AU - Patterson, Christopher J.

AU - Treon, Steven P.

AU - Dimopoulos, Meletios A.

PY - 2016/9/8

Y1 - 2016/9/8

N2 - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.

AB - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.

UR - http://www.scopus.com/inward/record.url?scp=84987788570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987788570&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-04-711234

DO - 10.1182/blood-2016-04-711234

M3 - Review article

VL - 128

SP - 1321

EP - 1328

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -